Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RANDOMIZED, OPEN, MULTICENTER, PROSPECTIVE, PHASE II CLINICAL TRIAL OF DOXORUBICIN vs. TRABECTEDIN PLUS DOXORUBICIN IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED NON OPERABLE AND/OR METASTATIC SOFT TISSUE SARCOMAS.

Next Previous
Trial Profile

RANDOMIZED, OPEN, MULTICENTER, PROSPECTIVE, PHASE II CLINICAL TRIAL OF DOXORUBICIN vs. TRABECTEDIN PLUS DOXORUBICIN IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED NON OPERABLE AND/OR METASTATIC SOFT TISSUE SARCOMAS.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary) ; Doxorubicin
  • Indications Fibrosarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Neurofibrosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Results (n=140) assessing the predictive transcriptomic based signature for trabectedin efficacy in advanced soft tissue sarcoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jun 2017 Results (n=198) assessing role of FAS for trabectadin in second lines of advanced soft tissue sarcoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
  • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top